Andere talen Ligand Pharmaceuticals Incorporated

Aandelen

LGND

US53220K5048

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
72,32 ^USD	+1,26%		+2,77%	+1,26%

08/04	Ligand Pharmaceuticals Incorporated kondigt nieuwe gegevens aan over Topiram injectie, gepresenteerd op de 9e London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conferentie	CI
03/04	Ligand Pharmaceuticals benoemt Scott Plesha tot Chief Executive Officer	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024	23/04
Ligand Pharmaceuticals Incorporated : Certificate of Incorporation/Bylaws - Form 8-K	19/04
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI	04/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™	03/04
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	03/04
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	03/04
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference	05/03
Ligand Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	05/03
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/03
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	27/02
Ligand: Q4 Earnings Snapshot	27/02
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	27/02
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	27/02
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	27/02
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	22/02
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires	19/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ligand Pharmaceuticals Incorporated

Aandelen

LGND

US53220K5048

Andere talen

Filters